SCHEMBL20806065

SCHEMBL20806065

COc1ccc(-c2ccc(-c3ccc(-c4ccc(-c5ccc(OC)cc5F)s4)c4nsnc34)s2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 3/20 0.41
▸ CYP1B1 Q16678 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP2E1 P05181 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C8 P10632 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2A6 P11509 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP4B1 P13584 1/20 0.41
▸ CYP2B6 P20813 1/20 0.41
▸ CYP3A5 P20815 1/20 0.41
▸ CYP2A7 P20853 1/20 0.41
▸ CYP3A7 P24462 1/20 0.41
▸ CYP2F1 P24903 1/20 0.41
▸ CYP2C18 P33260 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ CYP2J2 P51589 1/20 0.41
▸ CYP4F2 P78329 1/20 0.41
▸ CYP4F8 P98187 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19682268 0.90 APP (0.41) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL16265326 0.89 AHR (0.38) CYP1A2CYP2C9CYP2C19CLK1PRKCZ
SCHEMBL22238960 0.87 AMY1A (0.39) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL22022025 0.86 APP (0.45) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL16265236 0.85 ESR1 (0.38) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL17642170 0.84 CYP1A1 (0.46) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL20806198 0.83 ESR1 (0.37) CYP1A2ESR1ESR2
SCHEMBL21935251 0.83 ESR1 (0.35) ESR1ESR2
SCHEMBL17641863 0.82 CYP1A1 (0.45) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4
SCHEMBL18464314 0.81 ESR1 (0.50) CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020158211-A1 LIQUID CRYSTAL COMPOSITE BODY, LIQUID CRYSTAL LIGHT CONTROL ELEMENT AND LIGHT CONTROL WINDOW JNC株式会社 2020-08-06 — — WO disclosed
EP-3458549-B1 LIQUID-CRYSTAL MATERIAL MERCK PATENT GMBH (DE) 2020-07-22 — — EP disclosed
EP-3400271-B1 LIQUID-CRYSTALLINE MIXTURES MERCK PATENT GMBH (DE) 2020-07-22 — — EP disclosed
EP-3400270-B1 DEVICE FOR REGULATING ENTRY OF LIGHT MERCK PATENT GMBH (DE) 2020-04-29 — — EP disclosed
US-10344217-B2 Device for controlling the passage of energy, containing a dichroic dye compound MERCK PATENT GMBH (DE) 2019-07-09 — — US disclosed
EP-3004251-B1 DEVICE FOR CONTROLLING THE PASSAGE OF ENERGY, CONTAINING A DICHROIC DYE COMPOUND MERCK PATENT GMBH (DE) 2019-03-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344217-B2 Device for controlling the passage of energy, containing a dichroic dye compound CRY1, SLC25A1, CRY2 CYP1A1 2357/4885CYP1B1 2170/4885CYP1A2 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback